Urovant Sciences Announces Positive Topline Results from Pivotal Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Mar. 19, 2019-- Urovant Sciences (Nasdaq: UROV),a clinical-stage biopharmaceutical company...